TDP-43 ALS和FTLD中的蛋白质病变:机制性见解和治疗方法
Shilpi Chauhan1, Preeti Maan1, Archna Panghal1
1Department of Pharmaceutical Sciences, Lloyd Institute of Management and Technology, Plot No.-11, Knowledge Park-II, Greater Noida, Uttar Pradesh, 201306, India.
CNS & neurological disorders drug targets
|July 7, 2025
概括
在ALS和FTLD中,TDP-43蛋白病理驱动神经退行. 这次审查涵盖了TDP-43的内容.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- TDP-43蛋白对于RNA代谢至关重要.
- 病理性TDP-43聚合物是ALS和FTLD的标志.
- TARDBP和其他基因中的基因突变与ALS有关.
研究的目的:
- 审查TDP-43在ALS和FTLD中的生理作用和病理机制.
- 为了突出细胞过程的底层TDP-43毒性.
- 总结TDP-43相关神经退行症的治疗策略.
主要方法:
- 对TDP-43研究的文献综述.
- 分析TDP-43在RNA代谢和细胞过程中的作用.
- 针对TDP-43病理的治疗方法的总结.
主要成果:
- TDP-43病理包括错位,聚合和RNA代谢受损.
- 毒性的机制包括受损的细胞过程和类传播.
- 治疗策略侧重于分散,错位化和上游功能障碍.
结论:
- 了解TDP-43的多方面的作用是对抗ALS和FTLD的关键.
- 针对TDP-43病理学提供了有前途的治疗途径.
- 需要进一步的研究,以克服开发有效治疗方法的挑战.
更多相关视频
13:31Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
Published on: February 12, 2015
8.9K
07:14Optogenetic Phase Transition of TDP-43 in Spinal Motor Neurons of Zebrafish Larvae
Published on: February 25, 2022
6.1K
相关概念视频
Alzheimer's Disease: Overview
675
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
675
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Parkinson's Disease: Overview
716
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
716
Long-term Potentiation
2.9K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
Hebbian LTP
LTP can occur when...
2.9K
Long-term Depression
2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.6K
